Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is poised for growth with their innovative technologies and expanding product portfolio, potentially gaining market share in the treatment of various eye conditions. With strong revenue growth and profitability expected, the stock could continue to increase in value. While risks such as competition and reimbursement changes exist, the potential for upside from product launches and pipeline successes can offset these risks.

Bears say

Glaukos is facing risks such as increased competition in the MIGS market, potential difficulties with reimbursements, and slower adoption of their pipeline products. Their proposed LCDs for iDose may provide some relief, but overall their impact is expected to be limited. While the company has seen positive financial results with growing revenue and improved margins, there is still a potential downside from lower-than-expected market growth and slower product launches. Despite a strong track record and a robust pipeline, these risks contribute to a negative outlook on Glaukos's stock as its future performance could be impacted.

Glaukos (GKOS) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Glaukos (GKOS) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $141.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $141.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.